
Sign up to save your podcasts
Or


Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).
Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).
Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."
Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.
Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments.
Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines.
Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.
In Part 2 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains the value of patients receiving molecular profiling of their tumor, the vital role of clinical trials, and the promise of immunotherapy for treating this type of lung cancer.
In Part 1 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains what doctors look for and ask about when diagnosing lung cancer, and how you can be sure you received the correct diagnosis.
Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.
From the publisher's feed